USA flag logo/image

An Official Website of the United States Government

Measuring metabolism of C-terminal fragments of amyloid beta in the human…

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
93338
Program Year/Program:
2009 / SBIR
Agency Tracking Number:
AG034725
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
C2N DIAGNOSTICS, LLC
4041 FOREST PARK AVE SAINT LOUIS, MO 63108-3213
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2009
Title: Measuring metabolism of C-terminal fragments of amyloid beta in the human central
Agency: HHS
Contract: 1R44AG034725-01
Award Amount: $133,098.00
 

Abstract:

DESCRIPTION (provided by applicant): This grant will seek to develop a methodology that will allow us to test whether a promising new class of drugs for Alzheimer's disease is having the desired effect in the human brain. This methodology will allow pharma ceutical companies to make informed decisions about which drugs to advance into late stage clinical trials, and to optimize dosing and administration schedules based on pharmacodynamic response. C2N Diagnostics has licensed the platform technology from Was hington University to carry out the company's stable isotope labeling kinetic (SILK) assay. This assay is used to measure production and clearance rates of proteins in the brain. Previously, this methodology has been applied to measuring production and cle arance of total A2 from the brain, and evaluating the biologic activity of certain compounds in clinical development for the treatment of Alzheimer's. To measure the biologic activity of an emerging class of compounds, gamma-secretase modulators, we need t o be able to measure the production and clearance of the individual A2 isoforms, specifically A2 38, 40 and 42. The experiments proposed in this grant will develop this methodology in Phase I of this grant. In Phase II, the methodology will be applied to a small patient study. Applying the technology to a proof of concept human study will greatly facilitate commercialization of the technology. Further, this technology will greatly enhance our understanding of how AD metabolism plays a role in the pathogenes is of the disease. PUBLIC HEALTH RELEVANCE: Alzheimer's disease is a growing problem with an estimated 5 million people currently affected in the US. There are currently no disease modifying drugs approved for AD, in part due to a paucity of relevant tools to measure biologic activity and clinical efficacy for these types of drugs. The proposed experiments are intended to allow C2N to help pharmaceutical companies optimize the quality of their drug development efforts and to expedite bringing promising dise ase modifying treatments to the clinic.

Principal Investigator:

Tim West

Business Contact:

Tim West
Small Business Information at Submission:

C2N DIAGNOSTICS, LLC
C2N DIAGNOSTICS, LLC 4041 FOREST PARK AVE SAINT LOUIS, MO 63108

EIN/Tax ID: 126142138
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No